

In The United States Designated Office

In re Application of:	Express Mail Label No.: EL277741295US
Inventor: Mary Jane Cardoso et al.	Group Art Unit: Not Yet Assigned
Application No: Not Yet Assigned	Examiner: Not Yet Assigned
Filed: Herewith	
For: Recombinant MVA Virus Expressing Dengue Virus Antigens, and the Use thereof in Vaccines	

PRELIMINARY AMENDMENT PURSUANT TO 37 C.F.R. § 1.121

Assistant Commissioner for Patents
BOX PCT
Washington, D.C. 20231

Sir:

Please amend the above-identified patent application as indicated below prior to calculating claim fees.

IN THE CLAIMS

✓
Cancel Claim 2, and amend Claims 1 and 3-10 as follows.

A1
1. (Amended) A recombinant MVA comprising [containing] and capable of expressing one or more DNA sequences selected from the group of DNA sequences encoding [dengue virus] antigens from each of the four dengue virus serotypes (type 1, 2, 3 and 4).

A2
cont'd
3. (Amended) A recombinant MVA according to Claim 1 [claims 1 to 2], wherein the dengue virus antigen is selected from the group consisting of preM, E and [/or] NS1 antigens.